← Leaderboards
Sushil K Mahata
Veterans Medical Research Fdn/San Diego
$3,445,996
Attributed
$3,941,887
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $501.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,941,887 · 7
VA$0 · 4
By mechanism
R21$1,651,410 · 4
P01$1,191,051 · 1
R01$922,341 · 1
R29$177,085 · 1
IS1$0 · 1
I01$0 · 2
Top collaborators
- Gourisankar Ghosh3 shared
- Xu Chen1 shared
Others in their field
Top investigators on “Chromogranin A”
- Kathryn Haskins · University Of Colorado Denver$7,208,814
- Vivian Y. H. Hook · University Of California San Diego$5,038,306
- Aaron W Michels · University Of Colorado Denver$3,958,333
- Daniel T O'Connor · University Of California San Diego$3,580,135
- Michael E Greenberg · Dana-Farber Cancer Institute$3,186,580
- Desmond Arthur Schatz · University Of Florida$2,780,326
Research focus
Chromogranin APeptidesCellsCatecholaminesHypertensionPathway InteractionsPlasmaGenesPhenotypeRegulationBaseKnockout MiceChga GeneTissuesNeurotransmittersInsulinPlayAffectKnock-OutNicotinePancreastatinChronicDiabetes MellitusChromogranins
Grant awards (29)
Catestatin regulation of tauopathy and its therapeutic potentials$405,625
R21 · FY2025 · AG · contact PI
Catestatin and its mimetic pharmacophore TKO-10-18 as potential therapies for age-associated muscle loss and the consequent frailty$0
I21 · FY2025 · VA · contact PI
Chromogranin A is an aging risk factor$182,954
R21 · FY2024 · AG · contact PI
Peptide therapy for age-associated gut dysmotility$176,015
R21 · FY2024 · AG · contact PI
Catestatin and its mimetic pharmacophore TKO-10-18 as potential therapies for age-associated muscle loss and the consequent frailty$0
I21 · FY2024 · VA · contact PI
Chromogranin A is an aging risk factor$229,662
R21 · FY2023 · AG · contact PI
Peptide therapy for age-associated gut dysmotility$222,779
R21 · FY2023 · AG · contact PI
The Role of Chromogranin A in Tauopathy$434,375
R21 · FY2021 · AG
Catestatin improves glucose homeostasis and insulin sensitivity in diet-induced obese mice$0
I01 · FY2021 · VA · contact PI
Catestatin improves glucose homeostasis and insulin sensitivity in diet-induced obese mice$0
I01 · FY2020 · VA · contact PI
ShEEP Request for ACQUITY UPLC H-Class PLUS Bio System$0
IS1 · FY2019 · VA · contact PI
Catestatin improves glucose homeostasis and insulin sensitivity in diet-induced obese mice$0
I01 · FY2019 · VA · contact PI
Catestatin improves glucose homeostasis and insulin sensitivity in diet-induced obese mice$0
I01 · FY2018 · VA · contact PI
Role of Chromogranin A in Metabolic Syndrome$0
I01 · FY2013 · VA · contact PI
Role of Chromogranin A in Metabolic Syndrome$0
I01 · FY2012 · VA · contact PI
Role of Chromogranin A in Metabolic Syndrome$0
I01 · FY2011 · VA · contact PI
Role of Chromogranin A in Metabolic Syndrome$0
I01 · FY2011 · VA · contact PI
In Vivo Chromaffin Granule depletion and Blood Pressure$241,144
P01 · FY2009 · HL · contact PI
Chromaffin Cell physiology: Novel molecular approaches$179,455
R01 · FY2009 · DA · contact PI
In Vivo Chromaffin Granule depletion and Blood Pressure$322,395
P01 · FY2008 · HL · contact PI
Chromaffin Cell physiology: Novel molecular approaches$179,455
R01 · FY2008 · DA · contact PI
In Vivo Chromaffin Granule depletion and Blood Pressure$217,129
P01 · FY2007 · HL · contact PI
Chromaffin Cell physiology: Novel molecular approaches$183,116
R01 · FY2007 · DA · contact PI
In Vivo Chromaffin Granule depletion and Blood Pressure$208,223
P01 · FY2006 · HL · contact PI
Chromaffin Cell physiology: Novel molecular approaches$187,975
R01 · FY2006 · DA · contact PI
In Vivo Chromaffin Granule depletion and Blood Pressure$202,160
P01 · FY2005 · HL
Chromaffin Cell physiology: Novel molecular approaches$192,340
R01 · FY2005 · DA
CHROMOGRANIN A--NICOTINIC SIGNALING AND DESENSITIZATION$89,851
R29 · FY2001 · DA
CHROMOGRANIN A--NICOTINIC SIGNALING AND DESENSITIZATION$87,234
R29 · FY2000 · DA